Cytokine Adsorption in Acute-on-chronic Liver Failure (CYTOHEP)
Cytokine Adsorption in Patients With Acute-on-chronic Liver Failure (CYTOHEP) - a Single Center, Open-label, Randomized, Controlled Intervention Trial
The CYTOHEP study is a prospective, randomized, single center, open-label, controlled intervention trial to assess the benefit of extracorporeal hemoadsorption using the CytoSorb device in patients with acute-on-chronic liver failure. The primary goal for this trial is to assess whether the CytoSorb device used in addition to continuous renal replacement therapy (CRRT) will be able to significantly reduce bilirubin in the patient blood as compared to the control group treated with CRRT alone (i.e., without extracorporeal hemoadsorption).
The rationale for this study is based on considerations about the role of systemic inflammation in acute decompensation of liver cirrhosis and ACLF, in-vitro data of the effectiveness CytoSorb for the removal of molecules with a pathophysiological role in acute-on-chronic liver failure, and recent reports on the successful use of extracorporeal hemoadsorption in combination with CRRT in critically ill patients with acute liver dysfunction.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Liver cirrhosis is a major healthcare problem. The clinical course of cirrhosis can be separated in compensated and decompensated cirrhosis. Patients with compensated cirrhosis are largely asymptomatic and the development of decompensating events is a major hallmark in the course of the disease as median survival decreases from 12 years to less than 2 years. The development of extrahepatic organ complications in decompensated cirrhosis has been identified as a major prognostic milestone and has been described as acute-on-chronic liver failure (ACLF). ACLF is understood as a dynamic process and may evolve within days leading to multi-organ failure with renal failure being the most common organ involvement (56%), followed by liver and coagulation failure (44% and 28%, respectively). ACLF is associated with a high 28-day mortality.
During recent years, systemic inflammation has been recognized as a major driver of hepatic decompensation and progression of liver cirrhosis to ACLF. Importantly, systemic inflammation was described as an important trigger for development of extrahepatic organ failures, such as renal failure, development of hepatopulmonary syndrome, cirrhotic cardiomyopathy and hepatic encephalopathy. Systemic inflammation is particularly relevant in the pathogenesis of acute hepatic decompensation and is also associated with reduced survival. Therefore, elimination of drivers of inflammatory response and inflammatory cytokines in addition to established therapeutic approaches aiming at a reduction of bacterial translocation and mitigation of portal hypertension may help control excessive inflammatory activity and thus support hepatic recompensation. Previous in-vitro examinations and studies in non-cirrhotic inflammatory disorders have shown that proinflammatory cytokines and other factors can effectively be removed by extracorporeal hemoadsorption in the CytoSorb adsorber.
The CYTOHEP study is designed as a prospective, randomized, single center, open-label, controlled intervention trial to assess the benefit of extracorporeal hemoadsorption using the CytoSorb device in patients with acute-on-chronic liver failure. The primary goal for this pilot trial is to assess whether the CytoSorb device used in addition to CRRT will be able to significantly reduce bilirubin in the patient blood as compared to the control group treated with CRRT alone (i.e., without extracorporeal hemoadsorption).
Within this trial, CRRT will be initiated early, i.e., in patients with acute kidney injury (AKI) Kidney Disease: Improving Global Outcome (KDIGO) stage 3. For safety assessment, a third group will be assessed without early initiation of CRRT and extracorporeal hemoadsorption. After trial inclusion, all patients will be randomized in a 1:1:1 fashion in one of the study groups.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Alexander Supady, MD, MPH
- Numéro de téléphone: 34010 +49761270
- E-mail: alexander.supady@uniklinik-freiburg.de
Sauvegarde des contacts de l'étude
- Nom: Dominik Bettinger, MD
- Numéro de téléphone: 34010 +49761270
- E-mail: dominik.bettinger@uniklinik-freiburg.de
Lieux d'étude
-
-
-
Freiburg, Allemagne, 79108
- Recrutement
- University Clinic Freiburg
-
Contact:
- Alexander Supady, Dr., MPH
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- adult patients (≥ 18 years) admitted to the University Medical Center Freiburg, Germany
- acute-on-chronic liver failure (ACLF) WITH acute kidney injury according to Kidney Disease: Improving Global Outcome (KDIGO) criteria stage 3 (≥ 3-fold increase of serum creatinine OR increase of serum creatinine to ≥ 4 mg/dl OR urine output ≤ 0.3 ml/kg/h for ≥ 24 hours OR anuria for ≥ 12 hours) AND serum bilirubin ≥ 5 mg/dl
Exclusion Criteria:
- known patient will against participation in the study or against the measures applied in the study
- a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours
- no complete remission of malignancy including hepatocellular carcinoma within the past 12 months
- patients on the waiting list for liver transplant or the potential option for being listed for liver transplant within the next 6 months
- liver cirrhosis in patients after liver transplantation
- ongoing intermittent or continuous renal replacement therapy before study inclusion
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: CRRT with cytokine adsorption
Patients will be treated with CRRT and extracorporeal hemoadsorption for 72 hours
|
device for extracorporeal hemoadsorption
continuous renal replacement therapy
|
|
Expérimental: CRRT without cytokine adsorption
Patients will be treated with CRRT without extracorporeal hemoadsorption for 72 hours
|
continuous renal replacement therapy
|
|
Aucune intervention: no CRRT, no cytokine adsorption
Patients will not receive CRRT, nor extracorporeal hemoadsorption.
CRRT will only be initiated in case of severe electrolyte disorders or unmanageable fluid overload
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Serum bilirubin
Délai: 72 hours
|
Serum bilirubin after 72 hours
|
72 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Survival time
Délai: 30 days
|
Survival time from baseline
|
30 days
|
|
Interleukin-6
Délai: 72 hours
|
Interleukin-6 after 72 hours
|
72 hours
|
|
Liver function parameters
Délai: 72 hours
|
Quick/INR, AST, ALT, AP, g-GT
|
72 hours
|
|
Blood lactate
Délai: 72 hours
|
Lactate concentration after 72 hours
|
72 hours
|
|
CLIF-SOFA-score
Délai: 72 hours
|
CLIF-SOFA-score
|
72 hours
|
|
MELD score
Délai: 72 hours
|
MELD score
|
72 hours
|
|
SOFA score
Délai: 72 hours
|
SOFA score
|
72 hours
|
|
SAPS II
Délai: 72 hours
|
SAPS II
|
72 hours
|
|
FIPS score
Délai: 72 hours
|
FIPS score
|
72 hours
|
|
Ventilator free days
Délai: 30 days
|
Ventilator free days (VeFD) in the first 30 days after randomization, where each day on invasive mechanical ventilation (IMV), non-invasive ventilation (NIV), or ECMO is defined as ventilator day.
VeFD=0, if the patient dies in the first 30 days after randomization
|
30 days
|
|
vasopressor dosage
Délai: 72 hours
|
dosage of epinephrine, norepinephrine, dobutamine, argipressin and terlipressin
|
72 hours
|
|
Vasopressor free days
Délai: 30 days
|
Vasopressor free days (VaFD) in the first 30 days after randomization, where each day with any dose of epinephrine, norepinephrine, dobutamine, argipressin or terlipressin is defined as vasopressor day.
VaFD=0, if the patient dies in the first 30 days after randomization
|
30 days
|
|
Dialysis free days
Délai: 30 days
|
Dialysis free days (DFD) in the first 30 days after randomization, where each day on renal replacement therapy (RRT) is defined as dialysis day.
DFD=0, if the patient dies in the first 30 days after randomization
|
30 days
|
|
Inflammatory biomarkers
Délai: 72 hours
|
A biomarker panel of pro- and anti-inflammatory cytokines (blood samples will be frozen and stored for later analyses, panel will be determined at the time of analysis)
|
72 hours
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Alexander Supady, MD, MPH, University Hospital Freiburg
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CYTOHEP
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .